| Symbol | NKTP |
|---|---|
| Name | NOK THERAPEUTICS INC |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | 16066 United States PA 2009 Mackenzie Way Suite 100 |
| Telephone | +1 7245040738 |
| Fax | — |
| — | |
| Website | https://www.noktx.com/ |
| Incorporation | US |
| Incorporated On | 2024 |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | — |
| Audit Status | AUDITED |
| Reporting Status | U.S. Reporting: SEC Reporting - Reg A |
| CIK | 0002038166 |
| Description | Nok Therapeutics Inc. is a developer of cell-based immunotherapies designed to treat cancer by restoring immune defense. The company offers autologous natural killer cell therapies with outpatient administration and repeat-dosing capability, enabling patients with high-risk relapse cancers to extend their remission and access treatment. Additional info from OTC: |
No news found.